Yahoo
NYSE - Nasdaq Real Time Price USD

Baxter International Inc. (BAX)

19.89 +0.50 (+2.58%)
At close: June 18 at 4:00:03 PM EDT
20.15 +0.26 (+1.31%)
After hours: June 18 at 7:53:01 PM EDT
Trade BAX on Coinbase
Chart Range Bar
Loading chart for BAX

News headlines Baxter International is making strides with its subsidiary's new SHIYA 3D surgical visualization platform, aiming to enhance microsurgery. Despite recent share gains, the company faces challenges with its stock underperforming compared to the S&P 500 over the past year.

Baxter International is making strides with its subsidiary's new SHIYA 3D surgical visualization platform, aiming to enhance microsurgery. Despite recent share gains, the company faces challenges with its stock underperforming compared to the S&P 500 over the past year.

Updated 14m ago · Powered by Yahoo Scout
  • Previous Close 19.39
  • Open 19.70
  • Bid 19.18 x 80000
  • Ask 19.99 x 100000
  • Day's Range 19.55 - 20.09
  • 52 Week Range 15.73 - 31.76
  • Volume 5,596,573
  • Avg. Volume 7,650,714
  • Market Cap (intraday) 10.273B
  • Beta (5Y Monthly) 0.64
  • PE Ratio (TTM) --
  • EPS (TTM) -1.91
  • Earnings Date (est.) Jul 30, 2026
  • Forward Dividend & Yield 0.20 (0.98%)
  • Ex-Dividend Date May 29, 2026
  • 1y Target Est 21.54

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

www.baxter.com

37,500

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BAX
4.19%
S&P 500 (^GSPC)
9.57%

1-Year Return

BAX
32.68%
S&P 500 (^GSPC)
25.41%

3-Year Return

BAX
53.33%
S&P 500 (^GSPC)
70.10%

5-Year Return

BAX
72.77%
S&P 500 (^GSPC)
80.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 2.7B
Earnings 188M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
1B
2B

Analyst Insights

View More

Analyst Price Targets

17.00
21.54 Average
19.89 Current
40.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/28/2026
Analyst Citigroup
Rating Action Downgrade
Rating Sell
Price Action Lowers
Price Target 19 -> 17

Statistics

View More

Valuation Measures

Annual
As of 6/18/2026
  • Market Cap

    10.27B

  • Enterprise Value

    17.94B

  • Trailing P/E

    --

  • Forward P/E

    10.47

  • PEG Ratio (5yr expected)

    36.68

  • Price/Sales (ttm)

    0.90

  • Price/Book (mrq)

    1.70

  • Enterprise Value/Revenue

    1.58

  • Enterprise Value/EBITDA

    23.92

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -9.70%

  • Return on Assets (ttm)

    2.85%

  • Return on Equity (ttm)

    -15.01%

  • Revenue (ttm)

    11.32B

  • Net Income Avi to Common (ttm)

    -981M

  • Diluted EPS (ttm)

    -1.91

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.02B

  • Total Debt/Equity (mrq)

    161.02%

  • Levered Free Cash Flow (ttm)

    900.88M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

19.89 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Early progress in turnaround strategy

    Based in Deerfield, Illinois, Baxter International provides critical care, nutrition, renal, hospital, and surgical products. The company has approximately 37,500 employees. BAX shares are a component of the S&P 500.

    Rating
    Price Target
  • Headlines remain the order of the day, with major stock indices lower on

    Headlines remain the order of the day, with major stock indices lower on Thursday as investors awaited developments in the Middle East that overshadowed the barrage of corporate earnings reports. In this ever-changing environment, the current newsflow has aggression increasing between the U.S. and Iran but no major outbreak as of yet. Domestically, markets will need to parse on Friday the news that the U.S. Court of International Trade struck down new 10% global tariffs imposed by President Trump, ruling them illegal because they overstepped presidential authority.

  • Baxter Earnings: Maintained 2026 Outlook Relieves Market

    Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

    Rating
    Price Target
  • Despite Near-Term Headwinds, Baxter Aims for a Turnaround Under New Management

    Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: